Tumor Biology

, Volume 36, Issue 11, pp 8537–8543 | Cite as

Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy

Research Article

Abstract

Although pretreatment neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), and platelet–lymphocyte ratio (PLR) are reportedly associated with clinical outcomes of many cancers, their roles in patients with bladder cancer (BCa) who undergo radical cystectomy (RC) have not been widely investigated. We analyzed relationships between preoperative NLR, LMR, PLR, and overall survival (OS) in 124 BCa patients undergoing RC. OS curves were drawn using the Kaplan–Meier method and evaluated using the log-rank test. Relationships between OS and potential confounding variables were determined using Cox’s proportional hazard regression model. Decreased LMR was associated with shorter OS (P = 0.012); OS in the low PLR group was significantly longer than that in the high PLR group (P = 0.029), and NLR was not significantly associated with oncological outcomes. However, after adjusting for confounding variables, patients in the high-LMR group indicated >30 % decreased mortality than the low-LMR group (hazard ratio 0.674; 95 % confidence interval 0.412–0.890; P = 0.003), and PLR was not an independent predictor of OS. Our results show that preoperative LMR is a better prognostic factor in BCa patients undergoing RC, compared with NLR and PLR.

Keywords

Bladder cancer Radical cystectomy Prognosis NLR LMR PLR 

Supplementary material

13277_2015_3613_MOESM1_ESM.docx (16 kb)
ESM 1(DOCX 15 kb)

References

  1. 1.
    Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: a pitch for multiple players. Front Oncol. 2013;3:90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Choi KW, Hong SW, Chang YG, Lee WY, Lee B, Paik IW, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014;86:309–13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Moriwaki T, Ishige K, Araki M, Yoshida S, Nishi M, Sato M, et al. Glasgow prognostic score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. Med Oncol. 2014;31:287.CrossRefPubMedGoogle Scholar
  8. 8.
    Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14:864–9.CrossRefPubMedGoogle Scholar
  9. 9.
    He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013;30:439.CrossRefPubMedGoogle Scholar
  10. 10.
    Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, et al. Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014;7:248–55.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One. 2014;9:e92079.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Li YL, Gu KS, Pan YY, Jiao Y, Zhai ZM. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large b-cell lymphoma. BMC Cancer. 2014;14:341.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wei X, Huang F, Wei Y, Jing H, Xie M, Hao X, et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large b-cell lymphoma. Leuk Res. 2014;38:694–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Kilincalp S, Coban S, Akinci H, Hamamc M, Karaahmet F, Coskun Y, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. Eur J Cancer Prev. 2015;24:328–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. J Thorac Oncol. 2015;10:280–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Kaynar M, Yildirim ME, Badem H, Cavis M, Tekinarslan E, Istanbulluoglu MO, et al. Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio. Tumour Biol. 2014;35:6601–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Potretzke A, Hillman L, Wong K, Shi F, Brower R, Mai S, et al. Nlr is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urol Oncol. 2014;32:631–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014;66:1157–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Temraz S, Mukherji D, Farhat ZA, Nasr R, Charafeddine M, Shahait M, et al. Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol. 2014;14:76.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 1990;76:655–63.PubMedGoogle Scholar
  21. 21.
    Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Soygur T, Beduk Y, Yaman O, Yilmaz E, Tokgoz G, Gogus O. Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma. Urology. 1999;53:88–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Kastelan Z, Lukac J, Derezic D, Pasini J, Kusic Z, Sosic H, et al. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res. 2003;23:5185–9.PubMedGoogle Scholar
  26. 26.
    Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Huang JJ, Li YJ, Xia Y, Wang Y, Wei WX, Zhu YJ, et al. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/t-cell lymphoma. BMC Cancer. 2013;13:222.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.CrossRefPubMedGoogle Scholar
  31. 31.
    Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Clifton MM, Psutka SP, Boorjian SA, Cheville JC, Thapa P, Thompson RH, et al. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2015;33:373–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of UrologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of UrologyThe Affiliated Hospital of Qingdao UniversityQingdaoChina

Personalised recommendations